PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026Open Forum Infectious Diseases0 citationsOpen Access

P-2127. Early Post-Lung Transplant (LTx) Infections in the Antimicrobial Prophylaxis Era

View Full Paper
AEAshley N EstesARAdam M ResslerAMAaron P. Milstone

Key Points

  • This research aims to identify the rates and risk factors for early infections following lung transplantation.
  • Retrospective cohort study of adult lung transplant recipients at Michigan Medicine.
  • Collected data on demographics, complications, and infections within 90 days post-transplantation.
  • Used Fisher’s exact tests, Wilcoxon rank-sum tests, and Kaplan-Meier curves for analysis.
  • 51.8% of lung transplant recipients experienced postoperative infections.
  • Bacterial infections were the most common, with pneumonia as the leading type.
  • Longer intubation duration and ECMO use were associated with increased infection risk.

Abstract

Abstract Background Despite widespread antimicrobial prophylaxis, infections remain a common complication after lung transplantation (LTx). This study aimed to identify the occurrence, risk factors, 66.7%), followed by viral (4; 7.8%) 5.8%). Most common site of infection were the lungs [pneumonia (32), tracheobronchitis (6), empyema (4) p=0.003). Positive donor culture/infection was associated with a lower risk of infection given all pt without infection had positive donor cultures. Most infections occurred 2 weeks after LTx, & more frequently among pt on ECMO (p=0.02) (Figure 1A&B). 7 pt died within 90 d after LTx, infection contributed to death in 2 pt. Conclusion Bacterial infections, mainly pneumonia, were most common within 30 d after LTx, ECMO & longer intubation increased the risk of infection. These findings emphasize the need for ongoing evaluation & adjustment of infection prevention strategies, including efforts to reduce invasive procedures after LTx . Positive donor cultures did not increase the risk for infection, likely due to our ongoing notification system. Disclosures Marisa H. Miceli, MD, F2G: PI in clinical trial|GSK: PI clinical trial|Pulmocide: PI in clinical trial|Scynexis: Advisor/Consultant

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Estes et al. (2026) studied this question.

synapsesocial.com/papers/6966e73f13bf7a6f02bffd4chttps://doi.org/10.1093/ofid/ofaf695.2291
Ask AI
Helpful
Bookmark
Share
View Full Paper